Atorvastatin and Aβ(1-40): not as simple as cholesterol reduction in brain and relevance to Alzheimer disease.

Article history: Received 12 October 2010 Revised 9 December 2010 Accepted 15 December 2010 Available online 28 December 2010 oligomeric peptide. Several cross-sectional or case control epidemiological studies have revealed a tight link between cholesterol-lowering drugs (statins or others) and up to as high as a 70% reduction of risk for the development of AD (Dufouil et al., 2005; Hajjar et al., 2002; Jick et al., 2000; Rockwood et al., 2002; Rodriguez et al., 2002; Wolozin et al.,